Akoya Biosciences (AKYA) Price & Analysis

Compare

145 Followers

AKYA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.93 - $3.42

Previous CloseN/A

Volume11.73K

Average Volume (3M)387.23K

Market Cap

$64.44M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.86

Next Earnings

Aug 11, 2025

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding49,954,000

10 Day Avg. Volume753,019

30 Day Avg. Volume387,233

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$1.29

Price Target Upside0.00%

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Market LeadershipAkoya Biosciences is an established leader in the rapidly advancing spatial biology market.

Partnerships And MergersThe merger is expected to yield approximately $40 million in annual cost synergies by the end of 2026.

Bears Say

Financial PerformanceRevenue decreased about 10% y/y to $16.6 million in 1Q25, missing both estimates and consensus.

Market SentimentInvestors appear skeptical of the deal synergies with Quanterix and believe the transaction ascribes an overly rich valuation for AKYA.

Revenue And EarningsRevenue estimates for '25 and '26 have been reduced from $91M and $107M to $81M and $93M.

Akoya Biosciences News

Four new option listings and three option delistings on July 9th

New option listings for July 9th include DTCBD Stock (DTCBD), Everus Construction Group Inc (ECG), Emera Incorporated (EMA),...

22d ago

ECG

EMA

Akoya Biosciences Completes Merger and Nasdaq Delisting

Akoya Biosciences ( ($AKYA) ) has issued an update. On July 8, 2025, Akoya Biosciences, a company involved...

23d ago

AKYA

Akoya Biosciences price target lowered to $1.14 from $3 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an...

2M ago

AKYA

QTRX

Cautious Outlook for Akoya Biosciences Amidst Competitive Pressures and Promising Long-Term Potential

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Akoya Biosciences (AKYA – Research Report) today and...

2M ago

AKYA

Akoya Biosciences Reports Q1 2025 Financial Results

Akoya Biosciences Inc ( ($AKYA) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

AKYA

Akoya Biosciences price target lowered to $1.08 from $1.80 at Canaccord

Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.08 from $1.80 and keeps a Hold...

2M ago

AKYA

QTRX

Cautious Hold Rating on Akoya Biosciences Amid Financial and Industry Challenges

Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Hold rating on Akoya Biosciences (AKYA – Research...

3M ago

AKYA

Quanterix price target lowered to $12 from $15 at Canaccord

Canaccord lowered the firm’s price target on Quanterix (QTRX) to $12 from $15 and keeps a Buy rating...

3M ago

AKYA

QTRX

Quanterix shareholder issues statement on Akoya Biosciences merger pact

Kent Lake, a holder of approximately 7.7% of the outstanding common stock of Quanterix (QTRX), issued the following...

3M ago

AKYA

QTRX

Quanterix downgraded to Market Perform from Outperform at Leerink

Leerink analyst Puneet Souda downgraded Quanterix (QTRX) to Market Perform from Outperform with a price target of $8,...

3M ago

AKYA

QTRX

Akoya Biosciences and Quanterix Amend Merger Agreement

Akoya Biosciences ( ($AKYA) ) just unveiled an announcement. On April 28, 2025, Akoya Biosciences and Quanterix Corporation...

3M ago

AKYA

Quanterix, Akoya Biosciences announce amended merger agreement

Quanterix (QTRX) and Akoya Biosciences (AKYA) announced an amendment to the terms of their previously announced merger agreement....

3M ago

AKYA

QTRX

Akoya Biosciences price target lowered to $1.80 from $3.50 at Canaccord

Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.80 from $3.50 and keeps a Hold...

3M ago

AKYA

Akoya expands portfolio with new ADC breast cancer assay at AACR 2025

Akoya Biosciences (AKYA) announced the availability of a new assay designed to advance antibody-drug conjugate development in breast...

3M ago

AKYA

AKYA FAQ

What was Akoya Biosciences Inc’s price range in the past 12 months?

Akoya Biosciences Inc lowest stock price was $0.93 and its highest was $3.42 in the past 12 months.

What is Akoya Biosciences Inc’s market cap?

Akoya Biosciences Inc’s market cap is $64.44M.

When is Akoya Biosciences Inc’s upcoming earnings report date?

Akoya Biosciences Inc’s upcoming earnings report date is Aug 11, 2025 which is in 11 days.

How were Akoya Biosciences Inc’s earnings last quarter?

Akoya Biosciences Inc released its earnings results on May 12, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.108.

Is Akoya Biosciences Inc overvalued?

According to Wall Street analysts Akoya Biosciences Inc’s price is currently same. Get more investment ideas with TipRanks Premium

Does Akoya Biosciences Inc pay dividends?

Akoya Biosciences Inc does not currently pay dividends.

What is Akoya Biosciences Inc’s EPS estimate?

Akoya Biosciences Inc’s EPS estimate is -0.21.

How many shares outstanding does Akoya Biosciences Inc have?

Akoya Biosciences Inc has 49,954,000 shares outstanding.

What happened to Akoya Biosciences Inc’s price movement after its last earnings report?

Akoya Biosciences Inc reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -12.069%.

Which hedge fund is a major shareholder of Akoya Biosciences Inc?

Currently, no hedge funds are holding shares in AKYA

Akoya Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-354.27%

Trailing 12-Months

Asset Growth

-27.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akoya Biosciences Inc

Akoya Biosciences, Inc. (AKYA) is a biotechnology company that focuses on developing and commercializing advanced spatial biology solutions. The company operates in the life sciences and healthcare sectors, providing innovative tools and technologies that enable researchers to visualize and quantify cell and tissue characteristics. Akoya’s core products include platforms like the CODEX and Phenoptics systems, which are used for high-resolution imaging and spatial phenotyping to enhance the understanding of complex biological systems and diseases.

Akoya Biosciences (AKYA) Earnings & Revenues

AKYA Earnings Data >

AKYA Stock 12 Month Forecast

Average Price Target

$1.29

▲(0.00%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.3453846153846154,1.3707692307692307,1.396153846153846,1.4215384615384616,1.446923076923077,1.4723076923076923,1.4976923076923077,1.523076923076923,1.5484615384615383,1.5738461538461537,1.5992307692307692,1.6246153846153846,{"y":1.65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.3176923076923077,1.3153846153846154,1.313076923076923,1.310769230769231,1.3084615384615386,1.3061538461538462,1.3038461538461539,1.3015384615384615,1.2992307692307692,1.296923076923077,1.2946153846153847,1.2923076923076924,{"y":1.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.3015384615384615,1.2830769230769232,1.2646153846153847,1.2461538461538462,1.2276923076923079,1.2092307692307693,1.1907692307692308,1.1723076923076925,1.153846153846154,1.1353846153846154,1.1169230769230771,1.0984615384615386,{"y":1.08,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.56,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >